No Mercy / No Malice: The Weight
Summary
Scott Galloway argues that GLP-1 drugs, not AI, offer the greatest asymmetric upside by transforming health and the economy. He details their efficacy, the duopoly of Eli Lilly and Novo Nordisk, and the critical issue of unequal access due to insurance barriers. The episode also explores downstream effects on fast food, apparel, and alcohol industries as consumer habits shift. Galloway concludes that GLP-1s provide a hopeful vision for improving quality of life, urging broader distribution rather than rationing.
Topics discussed
Sponsor ads for Odoo, Mount Sinai, and Fetch Pet Insurance
Intro: GLP-1s vs SpaceX and the nature of investment
The economic burden of obesity and GLP-1 potential
Drug innovations: Retatrutide, Zepbound, and oral pills
Declining obesity rates and barriers to access
Insurance coverage changes for Medicare and private plans
Eli Lilly's market dominance and the subscription model
Downstream effects on fast food, apparel, and alcohol
GLP-1s as a hopeful vision compared to AI narratives
Closing thoughts and sponsor ads for Pure Leaf and Odoo
Listen ad-free on Castria